Hypera S.A Asset Resilience Ratio
Hypera S.A asset resilience ratio. Hypera S.A (HYPE3) has an Asset Resilience Ratio of 5.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HYPE3 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hypera S.A (2009–2025)
Asset resilience ratio of Hypera S.A from 2009 to 2025. This chart shows how Hypera S.A's Asset Resilience Ratio has changed over time. Read Hypera S.A balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hypera S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see HYPE3 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$1.64 Billion | 5.72% |
| Short-term Investments | R$0.00 | 0% |
| Total Liquid Assets | R$1.64 Billion | 5.72% |
Asset Resilience Insights
- Limited Liquidity: Hypera S.A maintains only 5.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Hypera S.A Industry Peers by Asset Resilience Ratio
Compare Hypera S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Hypera S.A Asset Resilience Ratio by Year (2009–2025)
Hypera S.A asset resilience ratio by year from 2009 to 2025. The table below shows the annual Asset Resilience Ratio data for Hypera S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.72% | R$1.64 Billion ≈ $320.90 Million |
R$28.59 Billion ≈ $5.61 Billion |
-1.12pp |
| 2024-12-31 | 6.84% | R$1.68 Billion ≈ $329.79 Million |
R$24.56 Billion ≈ $4.82 Billion |
-3.56pp |
| 2023-12-31 | 10.41% | R$2.55 Billion ≈ $500.42 Million |
R$24.51 Billion ≈ $4.81 Billion |
-0.83pp |
| 2022-12-31 | 11.23% | R$2.67 Billion ≈ $523.67 Million |
R$23.76 Billion ≈ $4.66 Billion |
+2.57pp |
| 2021-12-31 | 8.66% | R$1.72 Billion ≈ $336.94 Million |
R$19.82 Billion ≈ $3.89 Billion |
-13.83pp |
| 2020-12-31 | 22.49% | R$3.88 Billion ≈ $761.38 Million |
R$17.25 Billion ≈ $3.38 Billion |
+10.58pp |
| 2019-12-31 | 11.92% | R$1.42 Billion ≈ $278.77 Million |
R$11.92 Billion ≈ $2.34 Billion |
-1.53pp |
| 2018-12-31 | 13.45% | R$1.42 Billion ≈ $278.53 Million |
R$10.56 Billion ≈ $2.07 Billion |
+1.52pp |
| 2017-12-31 | 11.93% | R$1.21 Billion ≈ $237.13 Million |
R$10.13 Billion ≈ $1.99 Billion |
+2.71pp |
| 2016-12-31 | 9.22% | R$1.05 Billion ≈ $205.90 Million |
R$11.38 Billion ≈ $2.23 Billion |
+11.90pp |
| 2015-12-31 | -2.68% | R$-423.77 Million ≈ $-83.15 Million |
R$15.82 Billion ≈ $3.10 Billion |
-0.50pp |
| 2014-12-31 | -2.17% | R$-301.92 Million ≈ $-59.24 Million |
R$13.89 Billion ≈ $2.73 Billion |
-1.52pp |
| 2013-12-31 | -0.65% | R$-81.63 Million ≈ $-16.02 Million |
R$12.50 Billion ≈ $2.45 Billion |
-0.04pp |
| 2012-12-31 | -0.62% | R$-78.00 Million ≈ $-15.31 Million |
R$12.66 Billion ≈ $2.48 Billion |
-0.63pp |
| 2011-12-31 | 0.01% | R$1.71 Million ≈ $335.93K |
R$13.33 Billion ≈ $2.61 Billion |
+0.35pp |
| 2010-12-31 | -0.34% | R$-33.87 Million ≈ $-6.65 Million |
R$9.99 Billion ≈ $1.96 Billion |
-0.22pp |
| 2009-12-31 | -0.12% | R$-7.28 Million ≈ $-1.43 Million |
R$6.09 Billion ≈ $1.20 Billion |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more